WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2008099278) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR CCR5 ANTAGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/099278    International Application No.:    PCT/IB2008/000361
Publication Date: 21.08.2008 International Filing Date: 08.02.2008
IPC:
A61K 31/40 (2006.01), A61K 31/4439 (2006.01), A61K 31/46 (2006.01), A61K 31/506 (2006.01)
Applicants: PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GN) (For All Designated States Except US).
FELSTEAD, Stephen, John [GB/GB]; (GB) (For US Only).
HOPKINS, Andrew, Lee [GB/GB]; (GB) (For US Only).
MAYER, Howard, Bernard [US/US]; (US) (For US Only).
McHALE, Mary [GB/GB]; (GB) (For US Only)
Inventors: FELSTEAD, Stephen, John; (GB).
HOPKINS, Andrew, Lee; (GB).
MAYER, Howard, Bernard; (US).
McHALE, Mary; (GB)
Agent: DROUIN, Stéphane; Pfizer Research and Development, Ramsgate Road, Kent, Sandwich CT13 9NJ (GB)
Priority Data:
60/890,096 15.02.2007 US
Title (EN) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR CCR5 ANTAGONISTS
(FR) COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS POUR LA FABRICATION D'ANTAGONISTES CCR5
Abstract: front page image
(EN)The present invention relates to a CCR5 antagonist compound for elevating high density lipoprotein (HDL) particles in a patient, improving plasma lipid profile in a patient or reducing triglycerides in a patient. The invention also relates to a pharmaceutical composition comprising a CCR5 antagonist compound, an HMG-CoA reductase inhibitor compound and a pharmaceutically acceptable carrier. The invention also relates to a pharmaceutical composition comprising a CCR5 antagonist compound, a cholesteryl ester transfer protein (CETP) inhibitor compound and a pharmaceutically acceptable carrier.
(FR)La présente invention porte sur un composé antagoniste CCR5 pour augmenter les particules de lipoprotéine de haute densité (HDL) dans un patient, améliorer le profil lipidique dans le plasma d'un patient ou réduire les triglycérides dans un patient. L'invention porte également sur une composition pharmaceutique comprenant un composé antagoniste CCR5, un composé inhibiteur de HMG-CoA réductase et un support pharmaceutiquement acceptable. L'invention porte également sur une composition pharmaceutique comprenant un composé antagoniste CCR5, un composé inhibiteur de la protéine de transfert d'ester cholestérylique (CETP) et un support pharmaceutiquement acceptable.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)